PE20171449A1 - Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos - Google Patents
Derivados de nucleosidos sustituidos utiles como agentes antineoplasicosInfo
- Publication number
- PE20171449A1 PE20171449A1 PE2017001447A PE2017001447A PE20171449A1 PE 20171449 A1 PE20171449 A1 PE 20171449A1 PE 2017001447 A PE2017001447 A PE 2017001447A PE 2017001447 A PE2017001447 A PE 2017001447A PE 20171449 A1 PE20171449 A1 PE 20171449A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- nucleosid
- substitute
- antineoplastic agents
- derivatives useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se refiere a un derivado de nucleosido sustituido de formula (I) o una sal farmaceuticamente aceptable, donde: R1 es (C3-C8)alquilo, (C1-C8)haloalquilo, entre otros; R2 es H, halogeno, entre otros; R3 es H, hidroxi, entre otros; Q esta ausente o es una porcion divalente de O, S, NH o (C1-C8)alquileno; U es OR6, SR6, entre otros; V, W,X son N o C, en donde si cada uno forma un enlace doble, cada uno es C; Y es CR10, N, entre otros; R10 es H, (C1-C8)alquilo, hidroxi, entre otros; R6 es H, (C1-C8)alquilo, entre otros; Z es CR12, N, NR12, entre otros; R12 es H, (C1-C8)alquilo, entre otros;----- es un enlace opcional, en donde no mas de dos ----- no adyacentes pueden estar presentes; m y n son 0-1. Es un compuesto seleccionado el (3,4-difluorofenil)(2S,3S,4R,5R)-3,4-dihidroxi-5-(4-metil-7H-pirrolo[2,3-d]pirimidin-7-il)tetrahidrofuran-2-il)metanona; entre otros. Tambien se refiere una composicion farmaceutica que lo comprenda. Dicho derivado es util como agente antineoplasico
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562119932P | 2015-02-24 | 2015-02-24 | |
US201562213801P | 2015-09-03 | 2015-09-03 | |
US201662279209P | 2016-01-15 | 2016-01-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20171449A1 true PE20171449A1 (es) | 2017-10-02 |
Family
ID=55451515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2017001447A PE20171449A1 (es) | 2015-02-24 | 2016-02-15 | Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos |
Country Status (29)
Country | Link |
---|---|
US (1) | US10428104B2 (es) |
EP (1) | EP3262057B1 (es) |
JP (1) | JP6584521B2 (es) |
KR (1) | KR20170119705A (es) |
CN (1) | CN107278205A (es) |
AU (2) | AU2016225133B2 (es) |
BR (1) | BR112017017396A2 (es) |
CA (1) | CA2921314A1 (es) |
CL (1) | CL2017002155A1 (es) |
CO (1) | CO2017008403A2 (es) |
CR (1) | CR20170384A (es) |
CU (1) | CU20170105A7 (es) |
DO (1) | DOP2017000195A (es) |
EA (1) | EA031895B1 (es) |
ES (1) | ES2792899T3 (es) |
GT (1) | GT201700189A (es) |
IL (1) | IL253637A0 (es) |
MX (1) | MX2017010844A (es) |
NI (1) | NI201700095A (es) |
PE (1) | PE20171449A1 (es) |
PH (1) | PH12017501413A1 (es) |
SG (1) | SG11201706050WA (es) |
SV (1) | SV2017005514A (es) |
TN (1) | TN2017000357A1 (es) |
TW (1) | TWI622595B (es) |
UA (1) | UA118315C2 (es) |
UY (1) | UY36564A (es) |
WO (1) | WO2016135582A1 (es) |
ZA (1) | ZA201705092B (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR104326A1 (es) * | 2015-05-04 | 2017-07-12 | Lilly Co Eli | Compuestos nucleósidos 5-sustituidos |
TW202321249A (zh) | 2015-08-26 | 2023-06-01 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
WO2017153186A1 (en) | 2016-03-10 | 2017-09-14 | Janssen Pharmaceutica Nv | Substituted nucleoside analogues for use as prmt5 inhibitors |
JP6909799B2 (ja) * | 2016-03-10 | 2021-07-28 | ヤンセン ファーマシューティカ エヌ.ベー. | Prmt5阻害剤として使用するための置換ヌクレオシドアナログ |
US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
MX2019002959A (es) | 2016-09-14 | 2019-07-04 | Janssen Pharmaceutica Nv | Inhibidores biciclicos condensados de la interaccion de menina-mll. |
KR102493644B1 (ko) | 2016-09-14 | 2023-01-30 | 얀센 파마슈티카 엔.브이. | 메닌-mll 상호작용의 스피로 바이사이클릭 억제제 |
EP3519413A1 (en) | 2016-10-03 | 2019-08-07 | Janssen Pharmaceutica NV | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
CA3044739A1 (en) | 2016-12-15 | 2018-06-21 | Janssen Pharmaceutica Nv | Azepane inhibitors of menin-mll interaction |
WO2018152501A1 (en) * | 2017-02-20 | 2018-08-23 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
WO2018152548A1 (en) * | 2017-02-20 | 2018-08-23 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
EA201990851A1 (ru) | 2017-02-24 | 2019-09-30 | Янссен Фармацевтика Нв | Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5 |
US11279970B2 (en) | 2017-02-27 | 2022-03-22 | Janssen Pharmaceutica Nv | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor |
WO2018160855A1 (en) | 2017-03-01 | 2018-09-07 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
ES2885180T3 (es) * | 2017-08-09 | 2021-12-13 | Prelude Therapeutics Inc | Inhibidores selectivos de la proteína arginina metiltransferasa 5 (PRMT5) |
CN111542525B (zh) * | 2017-10-26 | 2023-06-27 | 普莱鲁德疗法有限公司 | 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂 |
EP3720865B1 (en) * | 2017-12-08 | 2024-03-13 | Janssen Pharmaceutica NV | Novel spirobicyclic analogues |
US11459330B2 (en) | 2017-12-13 | 2022-10-04 | Lupin Limited | Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors |
US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
US10711007B2 (en) | 2018-03-14 | 2020-07-14 | Prelude Therapeutics Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
JP7328241B2 (ja) * | 2018-03-14 | 2023-08-16 | プレリュード セラピューティクス,インコーポレイティド | タンパク質アルギニンメチルトランスフェラーゼ5(prmt5)の選択的阻害剤 |
WO2020033285A1 (en) * | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
CN113811539A (zh) * | 2019-02-13 | 2021-12-17 | 普莱鲁德疗法有限公司 | 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂 |
SG11202110272SA (en) * | 2019-03-25 | 2021-10-28 | California Inst Of Techn | Prmt5 inhibitors and uses thereof |
TW202112375A (zh) | 2019-06-06 | 2021-04-01 | 比利時商健生藥品公司 | 使用prmt5抑制劑治療癌症之方法 |
JP2022536337A (ja) | 2019-06-10 | 2022-08-15 | ルピン・リミテッド | Prmt5阻害剤 |
EP3983393A1 (en) | 2019-06-12 | 2022-04-20 | Janssen Pharmaceutica NV | Novel spirobicyclic intermediates |
CA3156135A1 (en) | 2019-10-22 | 2021-04-29 | Lupin Limited | PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITORS |
JP2023504279A (ja) | 2019-12-03 | 2023-02-02 | ルピン・リミテッド | Prmt5阻害剤としての置換ヌクレオシドアナログ |
PE20231308A1 (es) | 2020-08-18 | 2023-08-24 | Incyte Corp | Proceso e intermedios para preparar un inhibidor de jak1 |
IL300555A (en) | 2020-08-18 | 2023-04-01 | Incyte Corp | Process and intermediates for preparing a JAK inhibitor |
WO2022074391A1 (en) * | 2020-10-08 | 2022-04-14 | Storm Therapeutics Limited | Compounds inhibitors of mettl3 |
CN112679505B (zh) * | 2020-12-25 | 2022-04-22 | 杭州澳赛诺生物科技有限公司 | 一种4-甲基-7H-吡咯并[2,3-d]嘧啶的合成方法 |
WO2022153161A1 (en) | 2021-01-14 | 2022-07-21 | Pfizer Inc. | Treatment of cancer using a prmt5 inhibitor |
EP4370504A1 (en) | 2021-07-12 | 2024-05-22 | Incyte Corporation | Process and intermediates for preparing baricitinib |
WO2023017152A1 (en) * | 2021-08-13 | 2023-02-16 | Albert-Ludwigs-Universität Freiburg | Specific small molecule inhibitors that block kmt9 methyltransferase activity and function |
WO2024170488A1 (en) | 2023-02-13 | 2024-08-22 | Astrazeneca Ab | Prmt5 inhibitor for use in cancer therapy |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5795977A (en) * | 1989-09-15 | 1998-08-18 | Metabasis Therapeutics, Inc. | Water soluble adenosine kinase inhibitors |
US5646128A (en) * | 1989-09-15 | 1997-07-08 | Gensia, Inc. | Methods for treating adenosine kinase related conditions |
US5864033A (en) * | 1989-09-15 | 1999-01-26 | Metabasis Therapeutics, Inc. | Adenosine kinase inhibitors |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
GB9813554D0 (en) * | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
US6831069B2 (en) * | 1999-08-27 | 2004-12-14 | Ribapharm Inc. | Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
US7022681B2 (en) * | 2002-08-15 | 2006-04-04 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
EP2408306A4 (en) * | 2009-03-20 | 2012-11-07 | Alios Biopharma Inc | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGUES |
US20120077814A1 (en) | 2010-09-10 | 2012-03-29 | Zhong Wang | Sulfonamide, sulfamate, and sulfamothioate derivatives |
WO2013009735A1 (en) * | 2011-07-13 | 2013-01-17 | Merck Sharp & Dohme Corp. | 5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
WO2013044030A1 (en) * | 2011-09-23 | 2013-03-28 | Enanta Pharmaceuticals, Inc. | 2'-chloroacetylenyl substituted nucleoside derivatives |
EP3160477A4 (en) * | 2014-06-25 | 2018-07-04 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
AR104326A1 (es) * | 2015-05-04 | 2017-07-12 | Lilly Co Eli | Compuestos nucleósidos 5-sustituidos |
MX2018001073A (es) * | 2015-08-06 | 2018-06-12 | Chimerix Inc | Nucleosidos de pirrolopirimidina y analogos de los mismos utiles como agentes antivirales. |
-
2016
- 2016-02-15 MX MX2017010844A patent/MX2017010844A/es unknown
- 2016-02-15 EP EP16707209.9A patent/EP3262057B1/en active Active
- 2016-02-15 PE PE2017001447A patent/PE20171449A1/es unknown
- 2016-02-15 SG SG11201706050WA patent/SG11201706050WA/en unknown
- 2016-02-15 EA EA201791563A patent/EA031895B1/ru not_active IP Right Cessation
- 2016-02-15 AU AU2016225133A patent/AU2016225133B2/en not_active Ceased
- 2016-02-15 ES ES16707209T patent/ES2792899T3/es active Active
- 2016-02-15 BR BR112017017396A patent/BR112017017396A2/pt not_active Application Discontinuation
- 2016-02-15 TN TNP/2017/000357A patent/TN2017000357A1/en unknown
- 2016-02-15 WO PCT/IB2016/050803 patent/WO2016135582A1/en active Application Filing
- 2016-02-15 CN CN201680011823.1A patent/CN107278205A/zh active Pending
- 2016-02-15 JP JP2017544584A patent/JP6584521B2/ja not_active Expired - Fee Related
- 2016-02-15 UA UAA201708102A patent/UA118315C2/uk unknown
- 2016-02-15 KR KR1020177026762A patent/KR20170119705A/ko not_active Application Discontinuation
- 2016-02-15 CR CR20170384A patent/CR20170384A/es unknown
- 2016-02-15 CU CUP2017000105A patent/CU20170105A7/es unknown
- 2016-02-17 US US15/045,679 patent/US10428104B2/en active Active
- 2016-02-19 TW TW105104968A patent/TWI622595B/zh not_active IP Right Cessation
- 2016-02-19 CA CA2921314A patent/CA2921314A1/en not_active Abandoned
- 2016-02-22 UY UY0001036564A patent/UY36564A/es not_active Application Discontinuation
-
2017
- 2017-07-24 IL IL253637A patent/IL253637A0/en unknown
- 2017-07-26 ZA ZA2017/05092A patent/ZA201705092B/en unknown
- 2017-07-28 NI NI201700095A patent/NI201700095A/es unknown
- 2017-08-08 PH PH12017501413A patent/PH12017501413A1/en unknown
- 2017-08-14 SV SV2017005514A patent/SV2017005514A/es unknown
- 2017-08-17 CO CONC2017/0008403A patent/CO2017008403A2/es unknown
- 2017-08-21 DO DO2017000195A patent/DOP2017000195A/es unknown
- 2017-08-24 GT GT201700189A patent/GT201700189A/es unknown
- 2017-08-24 CL CL2017002155A patent/CL2017002155A1/es unknown
-
2018
- 2018-12-11 AU AU2018278842A patent/AU2018278842A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20171449A1 (es) | Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos | |
BR112015007698A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
PE20080361A1 (es) | Compuestos derivados de purina como activadores del receptor de adenosina a2a | |
PE20090511A1 (es) | Imidazopiridinonas | |
PE20080948A1 (es) | Derivados de imidazol como moduladores de la senda de hedgehog | |
PE20141828A1 (es) | 6-alquinilo piridinas como mimeticos smac | |
PE20081362A1 (es) | DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K | |
CO6220853A2 (es) | Derivados de pentafluorotiobenzamido acetonitrilo como agentes antiparasitarios | |
PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
PE20090714A1 (es) | Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido | |
PE20141228A1 (es) | Derivados de pirrolopirimidina y purina | |
PE20171155A1 (es) | Metodos y compuestos para tratar infecciones virales por paramyxoviridae | |
CR9459A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
AR072261A1 (es) | Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos. | |
PE20070179A1 (es) | Derivados de purina como agonistas del receptor de adenosina a2 | |
ECSP109932A (es) | Compuestos de biciclolactama sustituida | |
PE20090110A1 (es) | Compuestos macrociclicos derivados de amina como agentes inhibidores de hsp90 | |
PE20100055A1 (es) | Derivados de indolpiridina como moduladores de la sintasa de aldosterona | |
AR079746A1 (es) | Formulacion farmaceutica de anticuerpo | |
ECSP088623A (es) | Derivados de azepinoindol como agentes farmacéuticos | |
CR8756A (es) | Derivados de acido carboxilico bencimidazolona | |
GT200500292A (es) | Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica | |
PE20090070A1 (es) | Derivados de furano como agentes antiinfecciosos | |
AR072052A1 (es) | Derivados de indano como reguladores del receptor ampa | |
PE20060477A1 (es) | Compuestos piperazinodionas como antagonistas del receptor de oxitocina |